Imatinib-related interstitial lung disease.

Acute pulmonary complications in patients with hematologic malignancies.

Imatinib-induced dose-dependent interstitial lung disease successfully switched to nilotinib: a case report with concentration exposure data.

Interstitial pneumonitis in a patient with chronic myeloid leukemia.

Development of imatinibmesylate-induced interstitial lung disease 2 weeks after discontinuation of the treatment: a case report.

Lack of recurrence of imatinib-induced interstitial lung disease with nilotinib.

[A rare complication of imatinib mesylate therapy: drug-induced pneumonitis].

[Imatinib-induced pulmonary toxicity].

Drug-induced pneumonitis associated with imatinib mesylate in a patient with idiopathic pulmonary fibrosis.

Twenty-seven cases of drug-induced interstitial lung disease associated with imatinib mesylate.

Reversible drug-induced interstitial pneumonitis following imatinib mesylate therapy.

Corticosteroid-responsive interstitial pneumonitis related to imantinib mesylate with successful rechallenge, and potential causative mechanisms.

Imatinib mesylate-induced interstitial pneumonitis.

Challenging problems in advanced malignancy: Case 3. Imatinib mesylate-induced interstitial pneumonitis.

Hypersensitivity pneumonitis related to imatinib mesylate.